HC Wainwright Brokers Increase Earnings Estimates for Ocugen

Key Points

• HC Wainwright raised Ocugen's near‑term EPS forecasts (Q1–Q3 2026 to ($0.06), Q4 to ($0.07)) and lifted FY2026 to ($0.24) from ($0.29), but trimmed multi‑year projections including a sharp cut to FY2029 (to $0.26 from $0.84), signaling improved short‑term outlook but greater long‑term uncertainty.
• Ocugen completed enrollment in the Phase 3 trial of OCU400, an operational milestone, and reported Q1 EPS of ($0.06) in line with estimates, though revenue was minimal (~$0.19M) and margins/ROE remain deeply negative.
• Shares traded up about 6.6% to $1.77 with a 52‑week range of $0.52–$2.00; analyst coverage is mixed (two Buys, one Sell) with an average price target of $7.00 and a market cap near $580M.

Ocugen, Inc. (NASDAQ:OCGN - Free Report) - Analysts at HC Wainwright increased their Q1 2026 earnings per share estimates for Ocugen in a research report issued to clients and investors on Monday, March 9th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings per share of ($0.06) for the quarter, up from their previous estimate of ($0.07). The consensus estimate for Ocugen's current full-year earnings is ($0.20) per share. HC Wainwright also issued estimates for Ocugen's Q2 2026 earnings at ($0.06) EPS, Q3 2026 earnings at ($0.06) EPS, Q4 2026 earnings at ($0.07) EPS, FY2026 earnings at ($0.24) EPS, FY2027 earnings at ($0.28) EPS, FY2028 earnings at ($0.10) EPS and FY2029 earnings at $0.26 EPS.

Ocugen (NASDAQ:OCGN - Get Free Report) last issued its quarterly earnings results on Wednesday, March 4th. The company reported ($0.06) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.06). Ocugen had a negative net margin of 1,192.18% and a negative return on equity of 2,626.38%. The business had revenue of ($0.19) million for the quarter, compared to analyst estimates of $0.86 million.

Several other analysts also recently issued reports on the stock. Wall Street Zen downgraded shares of Ocugen from a "hold" rating to a "sell" rating in a research report on Saturday. Weiss Ratings reissued a "sell (e+)" rating on shares of Ocugen in a research note on Thursday, January 22nd. Finally, Chardan Capital reissued a "buy" rating and issued a $7.00 price target on shares of Ocugen in a report on Thursday, March 5th. Two research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Ocugen has an average rating of "Hold" and an average price target of $7.00.

Ocugen Trading Up 6.6%

Shares of OCGN opened at $1.77 on Wednesday. Ocugen has a fifty-two week low of $0.52 and a fifty-two week high of $2.00. The stock has a fifty day moving average of $1.59 and a two-hundred day moving average of $1.44. The company has a debt-to-equity ratio of 8.04, a quick ratio of 1.06 and a current ratio of 1.06. The company has a market capitalization of $580.38 million, a PE ratio of -7.70 and a beta of 2.75.

Hedge Funds Weigh In On Ocugen

Several hedge funds have recently added to or reduced their stakes in OCGN. Catalyst Funds Management Pty Ltd bought a new position in Ocugen during the 2nd quarter worth about $130,000. Caitong International Asset Management Co. Ltd raised its stake in Ocugen by 28,222.4% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 30,305 shares of the company's stock valued at $41,000 after acquiring an additional 30,198 shares during the period. Schonfeld Strategic Advisors LLC acquired a new stake in shares of Ocugen during the 4th quarter worth about $38,000. BNP Paribas Financial Markets boosted its holdings in shares of Ocugen by 56.7% during the second quarter. BNP Paribas Financial Markets now owns 36,822 shares of the company's stock worth $36,000 after acquiring an additional 13,326 shares during the period. Finally, SmartHarvest Portfolios LLC bought a new position in Ocugen during the 4th quarter worth $31,000. Institutional investors and hedge funds own 10.27% of the company's stock.

Key Ocugen News

Here are the key news stories impacting Ocugen this week:

• Positive Sentiment: HC Wainwright raised several 2026 quarterly and FY2026 EPS forecasts (Q1–Q3 moved to ($0.06), Q4 to ($0.07), FY2026 to ($0.24) from ($0.29)), signaling slightly improved near‑term profitability expectations. Read More.
• Positive Sentiment: Ocugen announced completion of enrollment in the Phase 3 trial of OCU400, a key operational milestone that de‑risks timing for pivotal data readouts and potential value inflection. Read More.
• Positive Sentiment: Company-released 2025 results and updates highlighted clinical progress across its gene‑therapy pipeline, supporting development momentum beyond single program headlines. Read More.
• Neutral Sentiment: HC Wainwright published an optimistic long‑term FY2030 EPS projection ($1.04), but this is a high‑uncertainty, model‑driven figure that may have limited near‑term market impact. Read More.
• Negative Sentiment: HC Wainwright trimmed multi‑year forecasts (FY2027, FY2028 and FY2029 estimates were reduced — FY2029 notably cut from $0.84 to $0.26), signaling weaker medium‑to‑longer‑term revenue/profit expectations and increased uncertainty around commercialization/timing. Read More.
• Negative Sentiment: A Seeking Alpha piece recommended downgrading the stock following OCU410 data, which could weigh on sentiment among value and momentum investors focused on near‑term data. Read More.

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.